Monselice

Researchers are conducting an observational, prospective, multicenter study in Italian cardiology centers to evaluate how well patients with Heart Failure with Reduced Ejection Fraction (HFrEF) follow guideline-recommended treatments. The study also aims to assess the safety of these treatments, monitor treatment patterns in patients with acute heart failure, and observe treatment approaches in all chronic heart failure patients regardless of their ejection fraction levels. The study involves two phases of educational interventions and data collection. Initially, healthcare providers will receive education on guideline recommendations and treatment patterns, followed by 3 months of patient data collection or up to 30 consecutive patients with chronic or acute heart failure. After 6 months, treatment modifications and outcomes will be evaluated. Then, a second educational session will highlight gaps between guidelines and practice, followed by another 3 months of data collection. Patients will be followed for 12 months total, with ongoing monitoring of treatment changes and outcomes. Participants will be assessed at enrollment and during the follow-up periods through clinical evaluations and data collection on treatment adherence and safety. The main outcome measured is adherence to guideline-directed medical therapies over 6 months. The study includes evaluations at 6 and 12 months after enrollment, with close monitoring of treatment patterns and patient health status throughout the study duration.

Pulmonary embolism (PE) is a major cause of death related to heart and blood vessel problems worldwide. This research aims to find the best timing for treatments that restore blood flow, called reperfusion, in patients with severe or intermediate-high risk PE. Current guidelines advise early reperfusion, but the exact timing is not clearly defined, unlike in heart attack or stroke care. Since most deaths from PE in hospitals happen early and blood clots change over time, knowing the best time to treat could improve survival and prevent worsening heart and circulation problems. The study will observe patients who receive reperfusion treatments, either with medicines that dissolve clots (systemic thrombolysis) or procedures that directly target clots through catheters (catheter-directed therapies). It is a national, multicenter, prospective study that focuses on how the timing of these treatments affects outcomes. The goal is to identify the optimal timing window that offers the most benefit, balancing effectiveness and safety, especially bleeding or heart-related complications. Participants will be monitored from enrollment until 30 days after treatment for outcomes including survival and complications. Data will be collected on patient condition, treatment timing, and clinical events. The study will help understand how reperfusion timing relates to in-hospital mortality and risks, supporting better management of high-risk and intermediate-high-risk PE. Participants must be adults diagnosed with intermediate-high or high-risk PE and able to consent to data use.